NANihan Ercioglu Akdogan

Nihan Ercioglu Akdogan

*This is an algorithmically generated author record based on publicly available information.

Nihan Ercioglu Akdogan has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Valorization of Ahlat Stone Wastes in the Production of Ceramic Tiles: Physical-Mechanical Properties

    by Nihan Ercioglu-Akdogan

    Ignimbrites (Ahlat Stone) with macro and micro-sized pores possessing independent of each other are volcanic rocks. It is mainly used as a building material because of its excellent insulation and easy to form material. The present study is aimed at producing floor tile which incorporated Ahlat stone as an alternative raw material for the ceramic industry. The effects of the increasing amount of Ahlat stone (1, 3 and 5 wt%) in the recipes on slurry rheology, physical properties of ceramic tiles, and sintering were studied. Chemical components of raw materials and Ahlat stone were determined using X-ray fluorescence spectroscopy and accordingly the recipes were created. The surface morphology of tiles was scanned using scanning electron microscope. When 3% Ahlat stone was added to the recipe, the flexural strength was calculated as 540 kgf.cm−2. This value is 22% higher than the value which is specified in the TSE standards. Therefore, tiles with a longer lifetime and more durability were developed. In addition, the increased amount of Ahlat stone in the recipe reduced the sintering temperature, thus energy saving was achieved during firing. GRAPHICAL ABSTRACT


  • Open Access

    Inhibition of mutagenic translesion synthesis: A possible strategy for improving chemotherapy?

    by Kinrin Yamanaka, Nimrat Chatterjee, Michael T. Hemann, Graham C. Walker

    DNA damaging chemotherapy is the first line of treatment for certain cancers, but its longterm success is often marred by the eventual acquisition of chemoresistance. Other cancers cannot be treated because they are intrinsically resistant to such chemotherapy. These 2 types of resistance are coupled in the context of translesion synthesis (TLS), which is carried out by specialized TLS DNA polymerases that can replicate past DNA lesions but in a lower fidelity manner. First, TLS DNA polymerases permit the bypass of modified DNA bases during DNA synthesis, thereby allowing proliferation to continue in the presence of chemotherapy, an issue of particular relevance to intrinsic drug resistance. Second, mistakes introduced by TLS polymerases copying over DNA lesions introduced during the chemotherapy lead to mutations that contribute to acquired resistance. These dual functions of mutagenic TLS polymerases with respect to chemoresistance make these proteins very promising targets for adjuvant therapy. The major branch of mutagenic TLS requires REV1, a Y family DNA polymerase that recruits other TLS polymerases with its C-terminal domain (CTD) including POL z, which is also required. Recent evidence obtained using mouse models is summarized, which shows that interfering with REV1/POL z-dependent mutagenic TLS during DNA damaging chemotherapy can help overcome problems due to both intrinsic resistance and acquired resistance. Ways to develop drugs that block mutagenic TLS are also considered, including taking advantage of structural knowledge to target